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Abstract
Recent randomized trials suggest that evidence-based algorithms for systemic sclerosis can be
developed to identify patients at risk for lung disease, follow lung disease progression, and modify
disease with therapies of proven benefit. Recognition of disease subsets allows physicians to integrate
physiology, overlapping disease manifestations, and predictable drug effects into a comprehensive
disease management program.
Introduction and context
Pulmonary disease is the leading cause of morbidity and
mortality from systemic sclerosis (SSc) [1]. The two most
common pulmonary complications of SSc are interstitial
lung disease (SSc-ILD) and pulmonary arterial hyperten-
sion (SSc-PAH). Management focuses on declaring all
SSc patients at risk for these complications, prompting
mandatory screening for lung disease.
SSc-ILD is present in up to 80% of patients when
objectively assessed with computed tomography (CT)
[2]. Defining who needs treatment remains controver-
sial. Similarly, SSc-PAH may be clinically silent at early
stages. Although the estimated prevalence of SSc-PAH is
27% [3], it tends to occur a decade or more following
disease onset [4].
The risk of SSc-ILD appears highest in the diffuse
cutaneous (dc-SSc) subset of disease, and the risk of
SSc-PAH appears highest in the limited cutaneous (lc-
SSc) subset. Gene expression studies reveal widespread
differences in the basic biological features of these two
subsets [5], with some experts considering them com-
pletely independent diseases. Recent studies, however,
show blurring of the clinical boundaries between the
subsets with regard to ILD risk [6].
dc-SSc, particularly if characterized by autoantibodies to
DNA topoisomerase-1 (anti-Scl-70) [7], frequently leads
to aggressive SSc-ILD. Since the greatest decline in forced
vital capacity (FVC) occurs within the first 5 years [8], all
patients should receive serial pulmonary function test-
ing. Screening CT remains controversial as many will be
abnormal in the absence of pulmonary symptoms or
evidence of declining lung function.
lc-SSc, characterized by an anti-centromere autoantibody
pattern on anti-nuclear antibody testing, often leads to
more severe vascular disease. Raynaud syndrome with
digital ulcerations frequently precedes SSc-PAH [4], the
most common cause of death in this subset. Diffusion
capacity of the lung for carbon monoxide (DLCO)
reduction in isolation [9] and an increased predicted
FVC percentage/predicted DLCO percentage ratio [4] are
risk factors. Right heart catheterization remains the gold
standard to confirm a PAH diagnosis.
Treatment of SSc-ILD to date has been haphazard, with a
variety of therapies applied and reported in case series
and randomized trials [10,11]. In the majority of
patients, the disease slowly progresses with an estimated
mortality of 42% within 10 years [12]. Therefore,
treatment trials to prove efficacy must be, by necessity,
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The previous 1-year mortality of 50% reported in SSc-
PAH [13], on the contrary, is not seen in the current
treatment era [14] as treatment options have expanded.
A broad consensus that long-term placebo-controlled
trials in SSc-PAH are not ethical has emerged, despite the
fact that none of the current drug trials has been
subjected to the rigors necessary to prove a survival
benefit of PAH drugs.
Another conundrum faced by physicians is the SSc
patient with both pulmonary hypertension (PH) and
SSc-ILD [15]. PH results from vascular destruction by the
fibrosis of ILD, pulmonary arteriolar remodeling and
plexiform arteriopathy (SSc-PAH), or pulmonary venous
hypertension due most commonly to a non-compliant
left ventricle (LV) resulting in diastolic dysfunction.
Pathologically, myocardial fibrosis without muscular




In clinical trials, the most robust endpoint for progres-
sive lung function decline in SSc-ILD is FVC; however,
the decline may not be linear. In a retrospective review
[17], if a baseline predicted FVC of less than 80%
occurred by 3 years compared with 5 years after disease
onset, a further decline of at least 15% was more likely in
the early-onset group.
Another study [18] defined disease extent on CT as mild
(<10% involvement) or extensive (>30% involvement)
and demonstrated that extensive disease was associated
with further FVC and DLCO decline, and a higher
mortality. Combined, these two studies suggest that early
ILD onset and more severe disease are more prone to
further advance. Biologically, the concept that fibrosis
begets more fibrosis implies that the patients likely to
benefit from treatment are those with the most extensive
disease.
The Scleroderma Lung Study (SLS) [19] and the
Fibrosing Alveolitis in Scleroderma Trial (FAST) [20],
using oral or intravenous cyclophosphamide (CYC),
respectively, showed comparable results of a modest
preservation of FVC in the CYC-treated subjects during
the time of active treatment. In SLS, secondary outcomes
also improved, including Short-Form 36 quality-of-life
scores [21]. These studies suggest that SSc-ILD is
treatable, but longer-term effective treatment options
are needed. Our current treatment practice is an
18-month oral CYC course, with dose determined by
toxicity monitoring, followed by a drug holiday.
Whether mycophenolate mofetil will be able to replace
or extend the CYC treatment effect remains to be
determined in clinical trials.
Pulmonary arterial hypertension
SSc-PAH therapy appears to improve survival compared
with historical controls [14]. Most clinical trial cohorts,
however, include SSc patients as a subgroup of other
PAH disease states. These studies conclude that the
outcome for SSc-PAH is not as good as for idiopathic
PAH [22], although the reason for this observation is
unclear. Most experts speculate that the systemic nature
of SSc adds vascular morbidity to other organ systems
and affects outcome. Furthermore, many SSc patients
enrolled in PAH trials are allowed to enter when a mild
amount of ILD or LV dysfunction is present.
SSc patients with both clinically significant ILD and PH,
however, are excluded from all current studies. Our
treatment experience is similar to that of others [23].
This group has high baseline predicted mortality and yet
can have a beneficial clinical response when thought-
fully treated for the individual disease components. We
begin with a right and left heart catheterization to
define the extent of LV disease before beginning therapy
for PAH, SSc-ILD, and LV diastolic dysfunction if
present. Since the 6-minute walk test is useful for
defining improvement in all of these disease states, we
use this test to define whether clinical improvement is
occurring, provided that the distance walked is dyspnea-
limited [24].
Implications for clinical practice
Every SSc patient should be screened with serial
spirometry. Abnormal spirometry should prompt a
more comprehensive evaluation with CT and echo-
cardiography. Dyspnea in the presence of normal spiro-
m e t r ys h o u l da l s ob ee v a l u a t e dw i t hC Ta n d
echocardiography, and if these prove normal, more
intensive evaluation should be done. Treatment deci-
sions for ILD include a thoughtful evaluation of disease
extent and patient preferences, since delays in treatment
until the predicted FVC is less than 70% or the CT extent
is greater than 30% could be associated with disabling
symptoms that may be incompletely reversed. Treatment
decisions concerning PAH therapy are currently based on
World Health Organization class and are similar to other
PAH disease states as recommended by guidelines [25].
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